Messenger RNA vaccines against SARS-CoV-2

doi:10.1016/j.cell.2020.12.039

. 2021 Mar 18;184(6):1401.

doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.

Messenger RNA vaccines against SARS-CoV-2

Eric J Topol¹

Affiliations

PMID: 33740443
PMCID: PMC7805392
DOI: 10.1016/j.cell.2020.12.039

Messenger RNA vaccines against SARS-CoV-2

Eric J Topol. Cell. 2021.

. 2021 Mar 18;184(6):1401.

doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.

Author

Eric J Topol¹

Affiliation

¹ Scripps Research, La Jolla, CA, USA. Electronic address: etopol@scripps.edu.

PMID: 33740443
PMCID: PMC7805392
DOI: 10.1016/j.cell.2020.12.039

Abstract

The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF.

PubMed Disclaimer

Cited by

Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ, Nace RA, Balakrishnan B, Zhang L, Packiriswamy N, Singh G, Warang P, Mena I, Narjari R, Vandergaast R, Peng K-W, García-Sastre A, Schotsaert M, Russell SJ. Muñoz-Alía MÁ, et al. mBio. 2024 Feb 14;15(2):e0292823. doi: 10.1128/mbio.02928-23. Epub 2024 Jan 9. mBio. 2024. PMID: 38193729 Free PMC article.
Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV_MT) in golden syrian hamster.
Ke Y, Zhang E, Guo J, Zhang X, Wang L, Chen D, Fang X, Zhu J, Li F, Sun T, Zhang B. Ke Y, et al. Acta Pharm Sin B. 2023 Dec;13(12):4856-4874. doi: 10.1016/j.apsb.2023.08.023. Epub 2023 Aug 25. Acta Pharm Sin B. 2023. PMID: 38045049 Free PMC article.
Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment.
Skwarek A, Gąsecka A, Jaguszewski MJ, Szarpak Ł, Dzieciątkowski T, Filipiak KJ. Skwarek A, et al. Arch Med Sci. 2021 Oct 15;19(5):1410-1420. doi: 10.5114/aoms/142103. eCollection 2023. Arch Med Sci. 2021. PMID: 37732058 Free PMC article.
Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus.
Furey C, Ye N, Kercher L, DeBeauchamp J, Crumpton JC, Jeevan T, Patton C, Franks J, Alameh MG, Fan SHY, Phan AT, Hunter CA, Webby RJ, Weissman D, Hensley SE. Furey C, et al. bioRxiv [Preprint]. 2023 Apr 30:2023.04.30.538854. doi: 10.1101/2023.04.30.538854. bioRxiv. 2023. PMID: 37162920 Free PMC article. Preprint.
Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes.
Zhou X, Lu H, Sang M, Qiu S, Yuan Y, Wu T, Chen J, Sun Z. Zhou X, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2184754. doi: 10.1080/21645515.2023.2184754. Epub 2023 Mar 2. Hum Vaccin Immunother. 2023. PMID: 36864628 Free PMC article.

See all "Cited by" articles

References

1. Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. mRNA-1273 Study Group An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med. 2020;383:1920–1931. - PMC - PubMed
1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. mRNA-1273 Study Group An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med. 2020;383:1920–1931. - PMC - PubMed

[2] Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. mRNA-1273 Study Group An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med. 2020;383:1920–1931. - PMC - PubMed

[3] Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. - PMC - PubMed

[4] Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Messenger RNA vaccines against SARS-CoV-2

Affiliation

Messenger RNA vaccines against SARS-CoV-2

Author

Affiliation

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous